Previous 10 | Next 10 |
home / stock / azn / azn articles
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slight...
In a move reminiscent of George Orwell's surveillance dystopia, companies are now deploying artificial intelligence (AI) to monitor commun...
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minera...
Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...
Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors w...
Pharmaceutical companies await the U.S. government’s forthcoming proposal, expected this Thursday, outlining substantial discounts for t...
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell ca...
AstraZeneca Plc (NASDAQ:AZN) released results from the EMERALD-1 Phase 3 trial of Imfinzi plus TACE concurrently, followed by Imfinz...
Thursday, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics Inc (NASDAQ:CYTK) acquisition, dealin...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...